MorphoSys AG is refocusing efforts on its mid- to late-stage oncology pipeline, including its myelofibrosis candidate pelabresib, after a year of ups and downs that culminated in cost-cutting measures announced earlier this month.
MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022
Cost-Cutting Measures In Place
The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.
